Yahoo Finance

Pykus Therapeutics Completes Trial Enrollment for PYK-2101, a Novel Retinal Sealant for the Treatment for Retinal Detachment

CAMBRIDGE, Mass., April 10, 2025 /PRNewswire/ -- Pykus Therapeutics, Inc. ("Pykus" or the "Company") announced today that it has completed enrollment of its pilot study (PYK-2101-RD001) in Australia.
Yahoo Finance

Pykus Therapeutics Expands Patent Portfolio for PYK-2101, a First-in-class Retinal Sealant Delivery Technology

-- PYK-2101 aims to provide rapid visual recovery, enhanced outcomes, and a dramatically improved post-operative experience for patients with retinal detachment, addressing critical unmet needs-- ...
Nature

Absence of marginal zone B cells in Pyk-2–deficient mice defines their role in the humoral response

The lymphoid organs contain specialized microanatomic structures composed of lymphoid, myeloid and stromal cells that are vital to the generation of an effective adaptive immune response. Although the ...
Medindia

Pykus Therapeutics Announces Positive Interim Pilot Clinical Trial Results of PYK-2101, a Novel Retinal Sealant

-- Results to date demonstrate rapid post-surgical visual recovery with no serious adverse events and meet or exceed FDA target rates for safety and effectiveness – -- Data presented today at ...
Nature

Allosteric pyruvate kinase-based “logic gate” synergistically senses energy and sugar levels in Mycobacterium tuberculosis

One of the reasons that the allosteric mechanisms regulating bacterial PYKs have remained elusive for decades is the lack of structural information about the binding of physiological effectors to ...